Acadia Pharmaceuticals, Inc. (ACAD) Tops Q2 EPS by 3c
Tweet
Share
E-mailGet Alerts ACAD Hot Sheet
Price: $29.58 +1.96%
Financial Fact:
Collaborative revenues: 5.27M
Today's EPS Names:
SCWO, HSAI, SYRS, More
Financial Fact:
Collaborative revenues: 5.27M
Today's EPS Names:
SCWO, HSAI, SYRS, More
Join SI Premium – FREE
Acadia Pharmaceuticals, Inc. (Nasdaq: ACAD) reported Q2 EPS of ($0.12), $0.03 better than the analyst estimate of ($0.15). Revenue for the quarter came in at $460 thousand versus the consensus estimate of $480 thousand.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- Acadia Pharmaceuticals (ACAD) PT Raised to $49 at UBS
- DocGo (DCGO) Misses Q2 EPS by 6c; Offers Guidance
- Klarna Group plc (KLAR) Tops Q2 EPS by 6c, Beats on Revenue; Offers FY26 Revenue Guidance
Create E-mail Alert Related Categories
EarningsSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
